1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Gene Therapy Market, by Type
8.1.1. Gene Silencing
8.1.1.1. Market Revenue and Forecast
8.1.2. Cell Replacement
8.1.2.1. Market Revenue and Forecast
8.1.3. Gene Augmentation
8.1.3.1. Market Revenue and Forecast
8.1.4. Other Therapies
8.1.4.1. Market Revenue and Forecast
9.1. Gene Therapy Market, by Vector
9.1.1. Viral Vectors
9.1.1.1. Market Revenue and Forecast
9.1.2. Non-Viral Vectors
9.1.2.1. Market Revenue and Forecast
10.1. Gene Therapy Market, by Therapeutic Area
10.1.1. Neurology
10.1.1.1. Market Revenue and Forecast
10.1.2. Oncology
10.1.2.1. Market Revenue and Forecast
10.1.3. Hepatology
10.1.3.1. Market Revenue and Forecast
10.1.4. Other Therapeutic Areas
10.1.4.1. Market Revenue and Forecast
11.1. Gene Therapy Market, by Delivery Method
11.1.1. In Vivo
11.1.1.1. Market Revenue and Forecast
11.1.2. Ex Vivo
11.1.2.1. Market Revenue and Forecast
12.1. Gene Therapy Market, by Route of Administration
12.1.1. Intravenous
12.1.1.1. Market Revenue and Forecast
12.1.2. Other
12.1.2.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Type
13.1.2. Market Revenue and Forecast, by Vector
13.1.3. Market Revenue and Forecast, by Therapeutic Area
13.1.4. Market Revenue and Forecast, by Delivery Method
13.1.5. Market Revenue and Forecast, by Route of Administration
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type
13.1.6.2. Market Revenue and Forecast, by Vector
13.1.6.3. Market Revenue and Forecast, by Therapeutic Area
13.1.6.4. Market Revenue and Forecast, by Delivery Method
13.1.6.5. Market Revenue and Forecast, by Route of Administration
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Type
13.1.7.2. Market Revenue and Forecast, by Vector
13.1.7.3. Market Revenue and Forecast, by Therapeutic Area
13.1.7.4. Market Revenue and Forecast, by Delivery Method
13.1.7.5. Market Revenue and Forecast, by Route of Administration
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type
13.2.2. Market Revenue and Forecast, by Vector
13.2.3. Market Revenue and Forecast, by Therapeutic Area
13.2.4. Market Revenue and Forecast, by Delivery Method
13.2.5. Market Revenue and Forecast, by Route of Administration
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type
13.2.6.2. Market Revenue and Forecast, by Vector
13.2.6.3. Market Revenue and Forecast, by Therapeutic Area
13.2.7. Market Revenue and Forecast, by Delivery Method
13.2.8. Market Revenue and Forecast, by Route of Administration
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type
13.2.9.2. Market Revenue and Forecast, by Vector
13.2.9.3. Market Revenue and Forecast, by Therapeutic Area
13.2.10. Market Revenue and Forecast, by Delivery Method
13.2.11. Market Revenue and Forecast, by Route of Administration
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type
13.2.12.2. Market Revenue and Forecast, by Vector
13.2.12.3. Market Revenue and Forecast, by Therapeutic Area
13.2.12.4. Market Revenue and Forecast, by Delivery Method
13.2.13. Market Revenue and Forecast, by Route of Administration
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type
13.2.14.2. Market Revenue and Forecast, by Vector
13.2.14.3. Market Revenue and Forecast, by Therapeutic Area
13.2.14.4. Market Revenue and Forecast, by Delivery Method
13.2.15. Market Revenue and Forecast, by Route of Administration
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type
13.3.2. Market Revenue and Forecast, by Vector
13.3.3. Market Revenue and Forecast, by Therapeutic Area
13.3.4. Market Revenue and Forecast, by Delivery Method
13.3.5. Market Revenue and Forecast, by Route of Administration
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type
13.3.6.2. Market Revenue and Forecast, by Vector
13.3.6.3. Market Revenue and Forecast, by Therapeutic Area
13.3.6.4. Market Revenue and Forecast, by Delivery Method
13.3.7. Market Revenue and Forecast, by Route of Administration
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type
13.3.8.2. Market Revenue and Forecast, by Vector
13.3.8.3. Market Revenue and Forecast, by Therapeutic Area
13.3.8.4. Market Revenue and Forecast, by Delivery Method
13.3.9. Market Revenue and Forecast, by Route of Administration
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type
13.3.10.2. Market Revenue and Forecast, by Vector
13.3.10.3. Market Revenue and Forecast, by Therapeutic Area
13.3.10.4. Market Revenue and Forecast, by Delivery Method
13.3.10.5. Market Revenue and Forecast, by Route of Administration
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type
13.3.11.2. Market Revenue and Forecast, by Vector
13.3.11.3. Market Revenue and Forecast, by Therapeutic Area
13.3.11.4. Market Revenue and Forecast, by Delivery Method
13.3.11.5. Market Revenue and Forecast, by Route of Administration
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type
13.4.2. Market Revenue and Forecast, by Vector
13.4.3. Market Revenue and Forecast, by Therapeutic Area
13.4.4. Market Revenue and Forecast, by Delivery Method
13.4.5. Market Revenue and Forecast, by Route of Administration
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type
13.4.6.2. Market Revenue and Forecast, by Vector
13.4.6.3. Market Revenue and Forecast, by Therapeutic Area
13.4.6.4. Market Revenue and Forecast, by Delivery Method
13.4.7. Market Revenue and Forecast, by Route of Administration
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type
13.4.8.2. Market Revenue and Forecast, by Vector
13.4.8.3. Market Revenue and Forecast, by Therapeutic Area
13.4.8.4. Market Revenue and Forecast, by Delivery Method
13.4.9. Market Revenue and Forecast, by Route of Administration
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type
13.4.10.2. Market Revenue and Forecast, by Vector
13.4.10.3. Market Revenue and Forecast, by Therapeutic Area
13.4.10.4. Market Revenue and Forecast, by Delivery Method
13.4.10.5. Market Revenue and Forecast, by Route of Administration
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type
13.4.11.2. Market Revenue and Forecast, by Vector
13.4.11.3. Market Revenue and Forecast, by Therapeutic Area
13.4.11.4. Market Revenue and Forecast, by Delivery Method
13.4.11.5. Market Revenue and Forecast, by Route of Administration
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type
13.5.2. Market Revenue and Forecast, by Vector
13.5.3. Market Revenue and Forecast, by Therapeutic Area
13.5.4. Market Revenue and Forecast, by Delivery Method
13.5.5. Market Revenue and Forecast, by Route of Administration
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type
13.5.6.2. Market Revenue and Forecast, by Vector
13.5.6.3. Market Revenue and Forecast, by Therapeutic Area
13.5.6.4. Market Revenue and Forecast, by Delivery Method
13.5.7. Market Revenue and Forecast, by Route of Administration
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type
13.5.8.2. Market Revenue and Forecast, by Vector
13.5.8.3. Market Revenue and Forecast, by Therapeutic Area
13.5.8.4. Market Revenue and Forecast, by Delivery Method
13.5.8.5. Market Revenue and Forecast, by Route of Administration
14.1. Dimension Therapeutics Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Taxus Cardium Pharmaceuticals Group Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Taxus Cardium Pharmaceuticals Group Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Shanghai Sunway Biotech Co. Ltd
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Applied Genetic Technologies Corporation
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Applied Genetic Technologies Corporation
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. American Gene Technologies
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. BioMarin Pharmaceuticals Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Gensight Biologics S.A.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Sibinono GeneTech Co. Ltd
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
